Details of the Drug

General Information of Drug (ID: DM9KNJT)

Drug Name
Vobarilizumab
Synonyms ALX-0061
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Phase 2 [1]
Systemic lupus erythematosus 4A40.0 Phase 2 [2]
Drug Type
Antibody
Cross-matching ID
UNII
9OD8ISS64U
DrugBank ID
DB14891
TTD ID
D9J6XV
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 6 receptor (IL6R) TT0E5SK IL6RA_HUMAN ; IL6RB_HUMAN Inhibitor [3]
Serum albumin (ALB) TTFNGC9 ALBU_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Rheumatoid arthritis
ICD Disease Classification FA20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 6 receptor (IL6R) DTT IL6R; IL6ST 5.77E-01 -0.24 -0.47
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02518620) An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02437890) A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Ablynx.